Precigen enters amended license with Alaunos for TCR products; Alaunos pays $75K annual fee

PRECIGEN, INC.

Precigen grants Alaunos exclusive, worldwide, royalty-free license for T-cell receptor products targeting neoantigens and HPV.
Alaunos also gets exclusive license for Sleeping Beauty technology for TCR products for neoantigens and shared antigens.
Alaunos pays $75,000 annual license fee; no milestones or royalties on products.
Alaunos loses rights to IL-12, CAR (CD-19, BCMA), and Gorilla IL-12 products; Precigen retains those.
Precigen may develop products outside the exclusive license; Alaunos can terminate on country/program basis.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PRECIGEN, INC. amended License Agreement with Alaunos Therapeutics valued at $75,000 (effective 2023-04-03).

Action: amendment
Agreement: license
Counterparty: Alaunos Therapeutics
Value: $75,000
Effective: 2023-04-03

Exact text from the filing

On April 3, 2023, Precigen, Inc., (the “Company”), entered into an amended and restated exclusive license agreement (the “License Agreement”), with Alaunos Therapeutics (“Alaunos”).

View on SEC.gov

23 material agreements filed in the last 30 days. Browse all material agreements →

PRECIGEN, INC. filing history →

Source: SEC EDGAR

accession 0000950103-23-005425

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.